headerseite_dna
headerseite_wabe
headerseite_bakterien
headerseite_nerv1
headerseite_nerv3
headerseite_binaer
headerseite_nerv1b
headerseite_erythrozyten
headerseite_nerv4
headerseite_chip
headerseite_nerv2
headerseite_befruchtung
headerseite_neurotrans

LOGO_TBDrug

 

 

A SME-STREP for Tuberculosis Drug Development


 

Date / Duration

2006-2009, 36 months

Funding

6th Framework Programme for Research and Technological Development of the European Commission (FP6); STREP

Budget

3'374'857 €

Partners

5 companies and universities from 4 countries

 

 tbdrugbilder

 

Description

Tuberculosis causes nearly two million deaths globally per year and has a devastating impact on developing countries. The disease kills more than 50% of the infected patients. The situation is getting worse due to growing resistance of mycobacterial strains to existing drugs and ever increasing human migration. These facts implicate the need for more efficient means of therapy both to reduce the number of deaths caused by tuberculosis and to allow more effective treatment of drug-resistant infections.

TBDRUG was funded under the 6th Framework Programme for Research and Technological Development with nearly two million € and teamed up five partners from four different countries. It aimed to establish an integrated drug discovery and development process to save the lives of thousands of infected individuals around the globe. The main goal of the project was to find new lead compounds suitable for drug development against several new targets of Mycobacterium tuberculosis.

At the end of the project, the consortium coordinated by the Hungarian SME Vichem Chemie Research Ltd. identified three promising lead candidates and is still working on them.

Read the final report of the project for more information.

Tasks EUrelations AG

EUrelations contributed substantially to the preparation of the successful proposal. Further, EUrelations was a partner in the project, supported the management and fulfilled certain dissemination activities.